Clinical Trial Search

Primary: PFS (Progression-Free Survival) — 27.71 Weeks

Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days

Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months

Primary: Disease-free Survival — 192; 197 Participants — p=0.737

Primary: Progression-free Survival — 12 Weeks

Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants

Primary: Percentage Change From Baseline in Tumour Size at 12 Weeks — -19.47; 19.65 Percentage change from baseline

Primary: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens — 10 Participants

Primary: Progression Free Survival (PFS) — 11 months

Primary: Response Rate — 8 Participants

Primary: Response Rate — 1; 9.4; 12.6; 76.8 Percentage of participants

Primary: Follow-up Duration — 1.07 years

Primary: Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo — NA; NA months — p=0.1649

Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 17 percentage of participants

Primary: Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0 — 9 Participants

Primary: Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease…

Primary: To Evaluate Efficacy of RAD001 as Monotherapy for the Treatment of Papillary Renal Cancer. Efficacy is Defined as the Percentage of Patients Progression-free at 6…

Primary: Best Overall Response Rate — 33 percentage of participants

Primary: Metabolic Response — 5 participants

Primary: Number of Participants With 18F-DCFPyL PET/CT Detected Sites of Metastatic Renal Cell Carcinoma (RCC) — 34 Participants

Primary: Percentage of Participants Who Experienced High-Grade (Grade 3-4 and Grade 5) Immune Mediated Adverse Events (IMAEs) — 4.1; 0; 0; 0 Percentage of participants

Primary: Number of Patients in Which the Treatment Was Tolerable — 5 Participants

Primary: Sensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT. — 0.76; 0.86; 0.86; 0.47 Proportion of participants — p=0.023

Primary: Progression-free Survival — 9.2; 4.2 months — p=.0000001

Primary: Progression Free Survival (PFS) — 5.5 Months

Primary: Percentage of Participants With Objective Response (OR) — 44.2 Percentage of participants

Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 13.5; 13.5 Percentage of participants

Primary: Progression-free Survival (PFS) - All Participants — 7.4 months

Primary: To Evaluate the Efficacy of Combining Everolimus and Bevacizumab in Patients With Advanced RCC of Non-clear Cell Histology — 78 percent of participants

Primary: Toxicities Measured Using CTCAE Version 4.03 — 4 participants with G3 TRAEs